FAQ/Help |
Calendar |
Search |
Today's Posts |
12-15-2009, 07:12 AM | #1 | |||
|
||||
Magnate
|
Chelsea Therapeutics Reports Subgroup Analysis of 44 Parkinson's Patients in Study 302 Shows Highly Statistically Significant Benefits of Droxidopa Therapy
Globe Newswire, December 14, 2009: 07:30 AM ET See: Droxidopa / Study 302, a Phase III
__________________
You're alive. Do something. The directive in life, the moral imperative was so uncomplicated. It could be expressed in single words, not complete sentences. It sounded like this: Look. Listen. Choose. Act. ~~Barbara Hall I long to accomplish a great and noble tasks, but it is my chief duty to accomplish humble tasks as though they were great and noble. The world is moved along, not only by the mighty shoves of its heroes, but also by the aggregate of the tiny pushes of each honest worker. ~~Helen Keller |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Droxidopa / Study 302, a Phase III | Parkinson's Disease Clinical Trials | |||
Oxford Biomedica Update On Phase I/II Study Of ProSavin® | Parkinson's Disease | |||
Spheramine(r) phase IIB study did not meet endpoints | Parkinson's Disease Clinical Trials | |||
5 Phase bone scan study | Reflex Sympathetic Dystrophy (RSD and CRPS) | |||
Successful Completion of Phase Ib Clinical Study for Myogane | ALS News & Research |